Reporter brief
Fisetin reduced inflammatory markers in elderly women with gait disturbance in a phase 2 RCT
What happened
AFFIRM was a phase 2 randomized placebo-controlled trial testing fisetin (a senolytic) in older women with gait disturbance. The study aimed to evaluate effects on insulin resistance markers, inflammation, bone resorption, and physical dysfunction. Specific results were not reported in the provided abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Elderly women with gait disturbance
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- May 11, 2026
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.